web analytics
25 C
Munich
Thursday, August 11, 2022

Trinity Resources Inc (OTCMKTS: TRRI) the Alzex Biomedical Reverse Merger

Trinity Resources Inc (OTCMKTS: TRRI) has made a colossal move on Friday after they reported Alzex Biomedical had reversed merged into the Company. TRRI which has an OS of just 1,505,268, with a float of just 437,088 shares was up over 1,000% on Friday hitting highs of $2.25 before giving up some of these gains. TRRI is a clean shell virtually debt free and the perfect reverse merger candidate and it has not dissapointed so far. Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars.  

Alzex Biomedical is a Canadian based development stage biopharmaceutical company which has developed and patented precision therapeutics for the treatment of Alzheimer’s Disease and other neurological diseases. It currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineering and research institute. This new class of drugs do not deploy any biological activity before they have crossed the blood-brain barrier, and hence do not induce significant side effects. The therapy can then target specific receptor sites in a more selective way, forming a superior delivery system through the blood-brain barrier. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Trinity Resources Inc (OTCMKTS: TRRI) was incorporated in the state of Delaware on March 11th, 1971. Operating as Hire International, Inc. up until September 30, 2012, the Company was a global provider of human resource solutions offering direct placement recruiting in a variety of fields, contingent staffing, employee benefits management and employee leasing. TRRI is the perfect merger candidate here, virtually debt free, very clean with just 1,505,268 shares OS, with a float of just 437,088 shares. 

Alzex Biomedical the new Company that merged into TRRI is a collaboration of researchers, scientists, and investors that have developed and patented precision therapeutics for the treatment of Alzheimers and other neurological diseases. Alzex currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineer and research institute. The Company’s North American headquarters are located in Vancouver B.C and its laboratories are located in France. 

On August 4, well after the closed TRRI announced following approval by a super majority of Alzex Biomedical Group Inc. (“Alzex”) shareholders obtained on June 30, 2022, it has now entered into a binding Asset purchase agreement (the “Agreement”) with Alzex whereby it will receive all of the assets and intellectual property (the “Assets”) of Alzex Biomedical. 

The purchase price for the Assets shall be ten million (10,000,000) restricted shares of Trinity’s Series A Convertible Preferred Stock. Trinity will also advance the sum of one hundred and fifty thousand dollars ($150,000 USD), to be disbursed by mutual agreement within the Alzex team, to settle certain outstanding liabilities of Alzex as well as to further secure and refile additional patent protection covering the acquired intellectual property. The shareholders of Trinity’s Series A Convertible Preferred Stock will retain security over the intellectual property until Trinity has successfully raised the first five million dollars ($5,000,000 USD) that shall be deployed towards the pre-clinical and clinical development of the acquired Alzex assets, at which point the preferred shares will automatically convert into common shares on a one-to-one basis. 

https://twitter.com/KickoStocks/status/1555596771564220416

To Find out the inside Scoop on TRRI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

TRRI

Additionally, Trinity will be issuing 20,000,000 of its Series B Convertible Preferred Shares, convertible on a one to one basis, which do not carry priority liquidation rights, nor a forced conversion. These shares will be allocated to the core French science team which developed the intellectual property which will form the basis of the Company going forward, as well as management and key advisors to the Company. 

Alzex is a Canadian based development stage biopharmaceutical company which has developed and patented precision therapeutics for the treatment of Alzheimer’s Disease and other neurological diseases. It currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineering and research institute. 

Alzex has devised an innovative therapeutic approach aimed at treating brain diseases by means of highly selective bio precursor drugs (prodrugs). The validity of this approach is evidenced by the company’s progress on Alzheimer’s Disease. The company has developed and patented two families of this new class of drugs, for which “proof of concept” in animal trials (in-vitro) has been established. 

This new class of drugs do not deploy any biological activity before they have crossed the blood-brain barrier, and hence do not induce significant side effects. The therapy can then target specific receptor sites in a more selective way, forming a superior delivery system through the blood-brain barrier. 

The therapy can then target specific receptor sites in a more selective way, forming a superior delivery system through the blood-brain barrier. This technology could potentially be applied to any number of brain diseases. 

Robert Rosner, President of Trinity Resources Inc. stated, “The acquisition of Alzex’s assets and intellectual property represents a major step in furthering our business plan and the Company’s transformation into a bio medical company. We will be able to utilize further the extensive research that’s been conducted to date to the benefit of our enlarged shareholder base, as well as patients and in need.” 

In the coming weeks it is anticipated that Mr. Fabrice Heitzmann, currently CEO of Alzex and a seasoned former Sanofi Aventis senior executive, will be joining Trinity’s board and management where he will play a leading role. The Company will be issuing a series of additional press releases in the future related to additional board and management changes as well as the composition of its newly formed scientific team. 

 For More on TRRI Subscribe Right Now!

TRRI is a clean shell virtually debt free and the perfect reverse merger candidate. As we have said many times before on this website, reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars. TRRI which has an OS of just 1,505,268, with a float of just 437,088 has certainly not disappointed so far running over 1,000% on Friday at its highs of $2.25. The new Company Alzex Biomedical is a Canadian based development stage biopharmaceutical company which has developed and patented precision therapeutics for the treatment of Alzheimer’s Disease and other neurological diseases. It currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineering and research institute. This new class of drugs do not deploy any biological activity before they have crossed the blood-brain barrier, and hence do not induce significant side effects. The therapy can then target specific receptor sites in a more selective way, forming a superior delivery system through the blood-brain barrier. We will be updating on TRRI when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TRRI either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.